Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Nevro Corp. (NYSE: NVRO) is a global medical device company headquartered in Redwood City, California and focused on technologies for chronic pain treatment. This news page aggregates company announcements, financial updates and clinical evidence related to Nevro’s proprietary 10 kHz spinal cord stimulation (SCS) therapy and sacroiliac (SI) joint fusion offerings.
Investors and observers can follow Nevro’s regular disclosures on quarterly and full-year financial results, including worldwide and U.S. revenue, international revenue, operating performance and cash position. The company also issues updates on strategic matters, such as its announced definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction, which remains subject to shareholder and regulatory approvals and other customary conditions.
Because Nevro operates in chronic pain management, a significant portion of its news flow highlights clinical and product developments. These include publications of data on 10 kHz SCS in painful diabetic neuropathy and Type 2 diabetes, showing durable pain relief and reported improvements in measures such as HbA1c, weight and sleep, as well as biomechanical studies of the Nevro1 SI Joint Fusion System. Product and regulatory updates, such as CE Mark Certification in Europe for the HFX iQ SCS system and launches of HFX iQ with HFX AdaptivAI, also feature prominently.
In addition, Nevro regularly announces employee inducement equity awards under NYSE Rule 303A.08, reflecting hiring activity, and provides commentary on commercial execution, restructuring efforts and marketing initiatives. For anyone tracking NVRO, this news feed offers a centralized view of Nevro’s financial performance, clinical evidence, product expansion and corporate transactions over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nevro Corp. (NYSE: NVRO) reported its Q1 2023 financial results, showcasing a worldwide revenue of $96.3 million, up 10% from Q1 2022. Sales for the Painful Diabetic Neuropathy (PDN) indication surged 160% to approximately $15.6 million. U.S. revenue grew 12% to $82.3 million, with U.S. trial procedures up 9%.
However, the company faced a net loss of $36.3 million, compared to a $32.8 million loss in Q1 2022. The company initiated the launch of its AI-powered HFX iQ Spinal Cord Stimulation System and anticipates second quarter revenue guidance of $110 to $112 million. The full-year guidance maintains a revenue expectation of $445 to $455 million, representing 10% to 12% growth.
Nevro Corp. (NYSE: NVRO) announces the enrollment of the first patient in its Painful Diabetic Neuropathy (PDN) Sensory Study, marking a significant step as it is the first prospective randomized controlled trial aimed at assessing neurological function restoration in patients with intractable PDN. The study will include up to 236 patients and compares conventional treatment methods against 10 kHz Therapy combined with conventional management, facilitating optional crossover after 6 months.
The FDA has granted Breakthrough Device Designation, expediting the review for market application and expanding Nevro’s labeling. This designation aims to improve patient access to effective treatment options for debilitating conditions. The trial aims to confirm the benefits of the proprietary 10 kHz Therapy and may support better reimbursement strategies for PDN coverage.
Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, has announced its participation in three significant investor conferences in May 2023. On May 10, CEO Kevin Thornal and CFO Rod MacLeod will present at the Bank of America 2023 Health Care Conference in Las Vegas at 5:00 pm PT. Following this, Rod MacLeod will present on May 16 at the JMP Securities Life Sciences Conference in New York at 11:00 am ET, and again on May 17 at the RBC Capital Markets Global Healthcare Conference at 11:30 am ET. Interested investors can access live webcasts and archived recordings from the events via Nevro's website. Nevro specializes in delivering innovative solutions for chronic pain, including the proprietary 10 kHz Therapy™ that benefits over 100,000 patients globally.
FAQ
What is the current stock price of Nevro (NVRO)?
What is the market cap of Nevro (NVRO)?
